Special Feature

User Panel

My Panel

My Panel

Bookmark Science Articles

Recent News
Bookmark / Share This Science Site

Efficacy of etanercept in patients with AA amyloidosis secondary to rheumatoid arthritis.

Efficacy of etanercept in patients with AA amyloidosis secondary to rheumatoid arthritis. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

  • Abstract Text of This Paper
  • Journal Published
  • MeSH Keywords of This Abstract
  • Chemicals and Substances Used in this Paper
  • Grants and Granting Agency of this Research
  • Database Accession Numbers Used in this Paper
  • Related Papers
  • Related Research Tags
  • Rate this Research Paper
  • Efficacy of etanercept in patients with AA amyloidosis secondary to rheumatoid arthritis. Abstract Text:

    t nakamuraT Nakamura,s higashiS Higashi,k tomodaK Tomoda,m tsukanoM Tsukano,s babaS Baba,t nakamuraT Nakamura,s higashiS Higashi,k tomodaK Tomoda,m tsukanoM Tsukano,s babaS Baba,t nakamuraT Nakamura,s higashiS Higashi,k tomodaK Tomoda,m tsukanoM Tsukano,s babaS Baba,

    OBJECTIVE: The efficacy of biological therapies in rheumatoid arthritis (RA) is well known, but their hypothetical benefit in amyloid A (AA) amyloidosis secondary to RA still remains to be considered. We evaluated the efficacy and safety of etanercept in serum amyloid A (SAA) 1.3 allele Japanese patients with AA amyloidosis secondary to RA. METHODS: Seven RA patients with histologically confirmed AA amyloidosis and renal involvement who were treated with etanercept were enrolled. They all had the SAA1.3 allele, which has been shown to be a risk factor not only for the association of AA amyloidosis but also for a poor prognosis in Japanese RA patients. Efficacy was assessed as a sustained decrease in RA inflammation and an amelioration of renal function. RESULTS: RA inflammation and AA amyloidosis were improved and stabilized after 43.4 +/- 16.5 weeks. At week 20 the number of tender (p = 0.017) and swollen (p = 0.017) joints, and levels of serum C-reactive protein (p = 0.018) and albumin (p = 0.045) had improved. The values for SAA, serum creatinine, calculated creatinine clearance, and proteinuria also ameliorated. No severe adverse events were observed. One patient eventually had to go on hemodialysis but her tolerance of etanercept remained stable. CONCLUSION: Etanercept can be used safely and effectively in AA amyloidosis secondary to RA with renal involvement, and is of clinical benefit in the short-term, even in patients on hemodialysis. It appears that SAA1.3 allele may be used as a clinical parameter for the introduction of etanercept in Japanese RA with AA amyloidosis.

    Efficacy of etanercept in patients with AA amyloidosis secondary to rheumatoid arthritis. Publishing Authors By Initials

    t nakamuraT Nakamura,s higashiS Higashi,k tomodaK Tomoda,m tsukanoM Tsukano,s babaS Baba,t nakamuraT Nakamura,s higashiS Higashi,k tomodaK Tomoda,m tsukanoM Tsukano,s babaS Baba,t nakamuraT Nakamura,s higashiS Higashi,k tomodaK Tomoda,m tsukanoM Tsukano,s babaS Baba,

    For similar abstracts research abstracts see: abstracts research

    PUBMED ID PMID:

    MEDLINE DATE:

    Efficacy of etanercept in patients with AA amyloidosis secondary to rheumatoid arthritis. Journal Published:

    PUBLICATION TYPE: Research Support, Non-U.S. Gov

    Journal: Clinical and experimental rheumatology

    VOLUME: 25

    Page Numbers: 518-22

    Journal Abbreviation: Clin. Exp. Rheumatol.

    ISSN: 0392-856X

    DAY: 24

    MONTH: 09

    YEAR: 2007

    Efficacy of etanercept in patients with AA amyloidosis secondary to rheumatoid arthritis. Information

    Number of References:

    LANGUAGE: eng

    NlmUniqueID: 8308521

    Efficacy of etanercept in patients with AA amyloidosis secondary to rheumatoid arthritis. Keywords Mesh Terms:

    KEYWORDS:

    MESH TERMS:

    Chemical & Substance for Abstract: Efficacy of etanercept in patients with AA amyloidosis secondary to rheumatoid arthritis. Information

    Substance Name:

    Registry Number:

    Grant and Affiliation Information for Efficacy of etanercept in patients with AA amyloidosis secondary to rheumatoid arthritis.

    AFFILIATION: Section of Internal Medicine and Rheumatology, Kumamoto Center for Arthritis and Rheumatology, Kumamoto, Japan. naktrkme@koh.marutakai.or.jp

    Country: Italy

    Italy Research PublicationItaly Research Publication

    AGENCY:

    GRANT:

    ACRONYM:

    MEDLINETA: Clin Exp Rheumatol

    REFSOURCE:

    DATABASENAME:

    ACCESSION NUMBER:

    Number Hits: 0

    Efficacy of etanercept in patients with AA amyloidosis secondary to rheumatoid arthritis Related Publications

     

    Molecular Station USER Menu

    Welcome to Molecular Station!

    You have to register before you can post on our forums or use our advanced features. Register Now! Its Free and Fast!

    Already registered? Login now below.

    User Name:

    Password:

    Already registered and Forgot your password? Click below to recover it.

    Recover Lost Password

    Join now - it's fast and free!

    Molecular Station is THE largest network of researchers, scientists and science lovers anywhere!

    Research Terms of Usage and Disclaimer
    Home
    Features

    Protocols

    DNA Forum

    Science Forum

    DNA Forum
    Biology Forum

    Science News


    [CaRP] XML error: Invalid document end at line 2

    For more click here:Science News